By Nicole Ireland THE CANADIAN PRESS Health Canada has approved a new antibody drug to help protect babies from serious illness caused by respiratory syncytial virus, or RSV.   Nirsevimab, also known by its brand name Beyfortus, was authorized on April 19. It was developed by AstraZeneca and Sanofi.   Nirsevimab is “a monoclonal antibody to prevent serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) infection in newborns and infants during their first RSV season,” Health Canada spokesman Mark Johnson said in an email to The Canadian Press on Friday.   The drug, which is given by injection, is also authorized for children up to two years of age if they are at risk of serious infection, he said.   Monoclonal antibodies are made in a laboratory

The post Health Canada approves new antibody drug to help prevent serious RSV in babies appeared first on The Turtle Island News.